When comparing poor CYP2D6 metabolizers to normal metabolizers, a more than twofold increased breast cancer–specific mortality rate was seen (HR, 2.59; 95% CI, 1.01 to 6.67) after adjusting for all the variables listed in Table 1. This evidence concerns the gene CYP2D6 and breast carcinoma.